WILMINGTON, Mass.--(BUSINESS WIRE)--AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced it was notified by the staff of the NYSE Amex that a review of the Company’s Form 10-Q for the period ended June 30, 2010 indicated that the Company is not in compliance with one of the NYSE Amex’s continued listing standards as set forth in Part 10 of the NYSE Amex’s Company Guide (the “Company Guide”). Specifically, the Exchange noted that the Company is not in compliance with Section 1003(a)(iii) of the Company Guide because it reported stockholders’ equity of less than $6,000,000 and losses from continuing operations and net losses in its five most recent fiscal years. As of June 30, 2010, the Company reported stockholders’ equity of $5,803,000.
